Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies315
  • 7D0.6%
  • 3M-2.2%
  • 1Y36.2%
  • YTD0.4%

In the last week, Pharma has been flat. The past year has been better, since the industry has gained 36% in that time. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026US$2.3tUS$405.9bUS$72.5b16.8x31.3x5.6x
Fri, 13 Mar 2026US$2.3tUS$406.1bUS$72.0b17.7x32.3x5.7x
Sun, 08 Feb 2026US$2.4tUS$411.7bUS$74.2b21.2x32.4x5.8x
Tue, 06 Jan 2026US$2.2tUS$402.6bUS$71.5b19.6x31.1x5.5x
Thu, 04 Dec 2025US$2.2tUS$402.7bUS$71.4b20x30.5x5.4x
Sat, 01 Nov 2025US$1.9tUS$396.3bUS$71.7b18.1x26.5x4.8x
Mon, 29 Sep 2025US$1.7tUS$387.9bUS$60.9b18.3x28.7x4.5x
Wed, 27 Aug 2025US$1.7tUS$387.8bUS$61.0b19.7x28.6x4.5x
Fri, 25 Jul 2025US$1.8tUS$384.0bUS$62.1b18.4x29.1x4.7x
Sun, 22 Jun 2025US$1.7tUS$382.7bUS$61.2b17.6x28.4x4.5x
Tue, 20 May 2025US$1.7tUS$382.6bUS$61.2b17.7x27.4x4.4x
Thu, 17 Apr 2025US$1.7tUS$380.5bUS$48.4b14.9x34.4x4.4x
Sat, 15 Mar 2025US$1.8tUS$380.5bUS$35.2b16.1x52.3x4.8x
Mon, 10 Feb 2025US$1.9tUS$380.7bUS$39.1b19.5x48x4.9x
Wed, 08 Jan 2025US$1.8tUS$369.3bUS$31.3b18.3x56.9x4.8x
Fri, 06 Dec 2024US$1.9tUS$373.8bUS$30.6b19.4x61.1x5x
Sun, 03 Nov 2024US$1.9tUS$373.2bUS$29.3b19.6x64.9x5.1x
Tue, 01 Oct 2024US$2.0tUS$364.1bUS$25.3b19.3x78.5x5.4x
Thu, 29 Aug 2024US$2.1tUS$363.3bUS$19.2b18x106.9x5.6x
Sat, 27 Jul 2024US$1.9tUS$356.5bUS$13.2b16.3x147.5x5.4x
Mon, 24 Jun 2024US$2.0tUS$358.2bUS$14.1b16.5x139x5.5x
Wed, 22 May 2024US$1.9tUS$358.3bUS$14.1b18.3x133.6x5.2x
Fri, 19 Apr 2024US$1.8tUS$357.7bUS$29.8b20.3x60.2x5x
Sun, 17 Mar 2024US$1.9tUS$355.4bUS$22.5b19.8x82.7x5.2x
Tue, 13 Feb 2024US$1.9tUS$354.7bUS$22.8b33.3x81.7x5.2x
Thu, 11 Jan 2024US$1.8tUS$375.2bUS$33.9b27.8x52.3x4.7x
Sat, 09 Dec 2023US$1.7tUS$375.1bUS$33.9b26.6x48.8x4.4x
Mon, 06 Nov 2023US$1.6tUS$376.9bUS$33.9b18.5x48.1x4.3x
Wed, 04 Oct 2023US$1.6tUS$381.8bUS$43.8b19x37.6x4.3x
Fri, 01 Sep 2023US$1.7tUS$381.4bUS$43.8b19.7x39.4x4.5x
Sun, 30 Jul 2023US$1.7tUS$393.6bUS$61.5b18.5x27.8x4.3x
Tue, 27 Jun 2023US$1.7tUS$392.8bUS$60.1b18.6x28.8x4.4x
Thu, 25 May 2023US$1.7tUS$392.9bUS$60.5b18.3x28.1x4.3x
Sat, 22 Apr 2023US$1.7tUS$402.6bUS$63.3b17.8x26.3x4.1x
Price to Earnings Ratio

26.3x


Total Market Cap: US$1.7tTotal Earnings: US$63.3bTotal Revenue: US$402.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 31.3x which is lower than its 3-year average PE of 53.7x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 4.6% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market4.44%
Healthcare2.18%
Pharma0.60%
Pharma0.60%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$240.100.7%
+US$4.1b		56.3%PE21.6x
TEVA Teva Pharmaceutical IndustriesUS$31.778.3%
+US$2.8b		133.6%PE26.2x
ZTS ZoetisUS$121.113.7%
+US$1.6b		-18.8%PE19.1x
MRK MerckUS$119.960.6%
+US$1.4b		53.0%PE16.2x
RGC Regencell Bioscience HoldingsUS$30.118.1%
+US$1.1b		3,444.6%PB3063.4x

Latest News

JNJ
US$240.10
Johnson & Johnson
7D
0.7%
1Y
56.3%
LLY
US$922.50
Eli Lilly
7D
-0.9%
1Y
21.8%
TEVA
US$31.77
Teva Pharmaceutical Industries
7D
8.3%
1Y
133.6%

Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy

Apr 14
MRK
US$119.96
Merck
7D
0.6%
1Y
53.0%
ANIP
US$78.29
ANI Pharmaceuticals
7D
-1.5%
1Y
12.6%
VTRS
US$13.91
Viatris
7D
5.7%
1Y
86.0%
SEPN
US$24.13
Septerna
7D
-2.9%
1Y
283.6%
RPRX
US$48.82
Royalty Pharma
7D
4.2%
1Y
50.4%
ZTS
US$121.11
Zoetis
7D
3.7%
1Y
-18.8%
SUPN
US$50.11
Supernus Pharmaceuticals
7D
-1.7%
1Y
59.3%

SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing

Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.
BIOA
US$16.57
BioAge Labs
7D
-5.9%
1Y
341.9%
BMY
US$58.08
Bristol-Myers Squibb
7D
0.7%
1Y
16.2%
ESPR
US$2.05
Esperion Therapeutics
7D
-11.3%
1Y
105.9%

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.
ARVN
US$11.00
Arvinas
7D
-3.3%
1Y
45.1%

ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Bullish Reassessment

Analysts have modestly raised the Arvinas fair value estimate from $14.56 to $14.88, reflecting higher Street price targets after recent Q4 model updates, expanded program timelines, and detailed cash runway assessments across multiple firms. Analyst Commentary Recent Street research presents a mixed but generally constructive picture for Arvinas, with several firms adjusting price targets higher following the Q4 update and program milestones.
RGC
US$30.11
Regencell Bioscience Holdings
7D
8.1%
1Y
3,444.6%
MAZE
US$27.68
Maze Therapeutics
7D
-2.3%
1Y
241.7%